A Phase 2/3 interventional study of TAK-881 and HYQVIA in Primary Immunodeficiency Diseases (PID), sponsored by Takeda. Completed at 32 sites in 8 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Takeda · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 4th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 2/3, and was the 18th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Takeda
Ages 6+
By country, each count listing its studies:
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 14 · Phase 4 2
First in 2002; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 47 across the 18 interventional studies, 113 across the 4 observational. Of the 19 that completed or were terminated, 12 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and pediatric participants with PIDD and compare them to HYQVIA in participants 16 years old and older.
The participants will be treated with TAK-881/HYQVIA or HYQVIA/TAK-881 with the same dose and dosing interval of immunoglobulin for up to 51 weeks (for participants greater than or equal to [>=]16 years) and only with TAK-881 for up to 27 weeks (for participants aged 2 to less than [\<]16 years) as they were treated with another immunoglobulin before enrollment. Participants will need to visit the clinic every 3 or 4 weeks during the duration of the study.
The study consists of a screening epoch, a ramp-up epoch (if needed) and treatment epochs. Participants who have been receiving conventional subcutaneous intravenous immunoglobin G (cIGSC) or intravenous immunoglobulin G (IGIV) before the study, will enter a ramp-up epoch which will start 1, 2, 3 or 4 weeks after the last cIGSC or IGIV pre study dose before screening. Participants who have already been receiving HYQVIA treatment before the study, will directly enter the treatment epochs after screening. Participants aged greater than or equal to [>=]16 years will be randomized at a 1:1 ratio to one of the following treatment sequences: either TAK-881 followed by HYQVIA or HYQVIA followed by TAK-881. Each participant aged >=16 years will complete both crossover epochs. Pediatric participants aged 2 to less than [\<]16 years will complete a single arm treatment with the study drug (TAK-881 only).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant has a serum trough level of IgG greater than (>) 5 grams per liter (g/L) at the following time points:
Informed Consent
Exclusion Criteria
Abnormal laboratory values at screening meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants aged \>=16 years will receive 6 or 8 infusions at full doses of TAK-881 followed by HYQVIA in sequence 1. The first full dose of TAK-881 will be administered either 2 weeks after the second ramp-up dose (applicable for participants pretreated with IGIV or cIGSC) or 3 or 4 weeks after the last infusion of their pre study immunoglobulin G (IgG) treatment (applicable for participants pre-treated with HYQVIA).
Biological: TAK-881 · Biological: HYQVIA
Participants aged \>=16 years will receive 6 or 8 infusions at full doses of HYQVIA followed by TAK-881 in Sequence 2. The first full dose of HYQVIA will be administered either 2 weeks after the second ramp-up dose (applicable for participants pretreated with IGIV or cIGSC) or 3 or 4 weeks after the last infusion of their pre study IgG treatment (applicable for participants pre-treated with HYQVIA).
Biological: TAK-881 · Biological: HYQVIA
Pediatric participants aged 2 to \<16 years will receive 6 or 8 infusions at full doses of TAK-881. The first full dose of TAK-881, will be administered either 2 weeks after the second ramp-up dose (applicable for participants pretreated with IGIV or cIGSC) or 3 or 4 weeks after the last infusion of their prestudy IgG treatment (applicable for participants pre-treated with HYQVIA).
Biological: TAK-881
Participants will receive SC infusion of TAK-881.
Also known as: Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20).
Drug pages: Immunoglobulin G · Hyaluronoglucosaminidase
Participants will receive SC infusion of HYQVIA.
Also known as: Immune Globulin Infusion (Human), 10% Solution with rHuPH20.
Area Under the Curve Over One Dosing Interval at Steady-State (AUC0-tau;ss) of Total IgG Levels With TAK-881 and HYQVIA Treatment in Participants >= 16 Years
AUC0-tau;ss was defined as the area under the curve over one dosing interval at steady-state. The AUC0-tau;ss was calculated during the dosing interval after the last dose in each crossover epoch by the non-compartmental analysis (NCA) based on total IgG levels for TAK-881 and HYQVIA.
Time frame: During the dosing interval of 8th dose (3-week) or 6th dose (4-week): 3-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21 days (post-infusion); 4-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21,28 days (post-infusion)
Mean Annualized Rate of All Infections
Mean annualized rates and corresponding two-sided 95% CIs were reported for TAK-881 and HYQVIA and were analyzed using a generalized linear model. The response distribution was assumed to be Poisson with a logarithmic link function. The model included the natural logarithm of the length of the observational period in years as an offset to account for potential differences in lengths of the observational periods per participant. Results were back transformed from the logarithmic scale.
Time frame: Single arm treatment: Up to 27 weeks; Crossover treatment: Up to 51 weeks
Mean Annualized Rate of Acute Serious Bacterial Infections (ASBIs)
Mean annualized rates of ASBIs and corresponding two-sided 95% CIs were reported for TAK-881 and HYQVIA and were analyzed using a generalized linear model. The response distribution was assumed to be Poisson with a logarithmic link function. The model included the natural logarithm of the length of the observational period in years as an offset to account for potential differences in lengths of the observational periods per participant. Results were back transformed from the logarithmic scale.
Time frame: Single arm treatment: Up to 27 weeks; Crossover treatment: Up to 51 weeks
Mean Annualized Rate of Fever Episodes
Mean annualized rates of fever episodes and corresponding two-sided 95% CIs were reported for TAK-881 and HYQVIA and were analyzed using a generalized linear model. The response distribution was assumed to be Poisson with a logarithmic link function. The model included the natural logarithm of the length of the observational period in years as an offset to account for potential differences in lengths of the observational periods per participant. Results were back transformed from the logarithmic scale.
Time frame: Single arm treatment: Up to 27 weeks; Crossover treatment: Up to 51 weeks
Time to First ASBI
The time to first ASBI was defined as the time between the first investigational product (IP) administration (referring to the first ramp-up dose, if ramp-up is applicable, or to the first full dose at Week 1, if ramp-up is not applicable) and the first occurrence of the ASBI. The median time to first ASBI was reported.
Time frame: Single arm treatment: Up to 27 weeks; Crossover treatment: Up to 51 weeks
Duration of Infections
The median duration of infections was reported. Only participants with an infection are included here.
Time frame: Single arm treatment: Up to 27 weeks; Crossover treatment: Up to 51 weeks
Number of Days Not Able to go to School, Work, Daycare, or to Perform Normal Daily Activities Due to Infections and/or Their Treatment, or Other Illnesses
The mean number of days with daily activity impairment per participant-year was reported.
Time frame: Single arm treatment: Up to 27 weeks; Crossover treatment: Up to 51 weeks
Number of Days on Antibiotics Due to Treatment of Infection
Days on antibiotics were calculated as the total number of calendar days during which at least one respective antibiotic was administered due to treatment of infection. Data was collected for administration via oral or parenteral and all routes. The mean number of days on antibiotics per participant-year was reported.
Time frame: Single arm treatment: Up to 27 weeks; Crossover treatment: Up to 51 weeks
Number of Participants Hospitalized Due to Infection or Other Illnesses
Number of participants hospitalized due to infection or other illnesses were reported.
Time frame: Single arm treatment: Up to 27 weeks; Crossover treatment: Up to 51 weeks
Number of Days of Hospitalization Due to Infections or Other Illnesses
The number of days of hospitalization due to infection per participant-year was reported.
Time frame: Single arm treatment: Up to 27 weeks; Crossover treatment: Up to 51 weeks
Number of Participants With Acute Physician Visits Due to Infection or Other Illnesses
Number of participants with acute physician visits due to infection or other illnesses was reported.
Time frame: Single arm treatment: Up to 27 weeks; Crossover treatment: Up to 51 weeks
Maximum Concentration (Cmax) of Total IgG With TAK-881 and HYQVIA at Steady-State in Participants >=16 Years
Cmax of total IgG with TAK-881 and HYQVIA at steady-state was reported.
Time frame: During the dosing interval of 8th dose (3-week) or 6th dose (4-week): 3-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21 days (post-infusion); 4-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21,28 days (post-infusion)
Time to Maximum Concentration (Tmax) of Total IgG With TAK-881 and HYQVIA at Steady-State in Participants >=16 Years
Tmax of total IgG with TAK-881 and HYQVIA at steady-state was reported.
Time frame: During the dosing interval of 8th dose (3-week) or 6th dose (4-week): 3-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21 days (post-infusion); 4-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21,28 days (post-infusion)
Terminal Half-life (t1/2) of Total IgG With TAK-881 and HYQVIA at Steady-State in Participants >=16 Years
t1/2 of total IgG with TAK-881 and HYQVIA at steady-state was reported. t1/2 was estimated by noncompartmental analysis from the terminal elimination-rate constant derived from the slope of the log-linear decline in total IgG concentrations during the terminal phase of the concentration-time profile. The estimated t1/2 may exceed the 21- or 28-day PK sampling interval. The PK assessment period did not extend beyond the protocol-defined 21-day or 28-day interval.
Time frame: During the dosing interval of 8th dose (3-week) or 6th dose (4-week): 3-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21 days (post-infusion); 4-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21,28 days (post-infusion)
Apparent Clearance (CL/F) of Total IgG With TAK-881 and HYQVIA at Steady-State in Participants >=16 Years
CL/F of total IgG with TAK-881 and HYQVIA at steady-state was reported.
Time frame: During the dosing interval of 8th dose (3-week) or 6th dose (4-week): 3-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21 days (post-infusion); 4-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21,28 days (post-infusion)
Apparent Volume of Distribution (Vz/F) of Total IgG With TAK-881 and HYQVIA at Steady-State in Participants >=16 Years
Vz/F of total IgG with TAK-881 and HYQVIA at steady-state was reported.
Time frame: During the dosing interval of 8th dose (3-week) or 6th dose (4-week): 3-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21 days (post-infusion); 4-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21,28 days (post-infusion)
AUC0-tau;ss Per Week (AUC0-tau;ss/Week) of Total IgG With TAK-881 and HYQVIA at Steady-State in Participants >=16 Years
AUC0-tau;ss/week of total IgG with TAK-881 and HYQVIA at steady-state was reported.
Time frame: During the dosing interval of 8th dose (3-week) or 6th dose (4-week): 3-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21 days (post-infusion); 4-week dosing - Day 1 (pre & post-infusion), 24,48,72 hours, 7,14,21,28 days (post-infusion)
Trough Level of Total IgG
The trough level of total IgG was reported. Total IgG trough levels were analyzed using the last trough level per participants (at the end of the last dosing interval).
Time frame: Single arm treatment: pre-infusion at Week 25 during the 4-week dosing; Crossover treatment: pre-infusion at Weeks 25, 49, corresponding to 21 days after the last dose for 3-week dosing and 28 days after the last dose for 4-week regimen
Trough Level of IgG Subclasses
The trough level of IgG subclasses was reported. Trough levels of IgG subclasses were analyzed using the last trough level per participants (at the end of the last dosing interval).
Time frame: Single arm treatment: pre-infusion at Week 21 during the 4-week dosing; Crossover treatment: pre-infusion at Weeks 25, 49, corresponding to 21 days after the last dose for 3-week dosing and 28 days after the last dose for 4-week regimen
Trough Level of Antigen Specific IgG Antibodies in Participants >=16 Years
The trough level of antigen specific IgG antibodies (Clostridium tetani toxoid, Haemophilus influenzae, and hepatitis B) was reported. Antigen-specific IgG antibodies were analyzed using the last trough level per participant in each crossover epoch (at the end of the last dosing interval).
Time frame: Crossover treatment: pre-infusion at Weeks 25, 49, corresponding to 21 days after the last dose for 3-week dosing and 28 days after the last dose for 4-week regimen
Simulated AUC0-tau;ss of TAK-881 at Steady-State
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. AUC0-tau;ss was estimated for the simulated PK profiles and summarized by age group. Geometric mean and 90% predicted interval (PI) derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
Time frame: During the dosing interval of 6th dose (4-week): From Day 1 (pre and post infusion) every day up to 4 weeks
Simulated Cmax of TAK-881 at Steady-State
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. Cmax was estimated for the simulated PK profiles and summarized by age group. Geometric mean and 90% PI derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
Time frame: During the dosing interval of 6th dose (4-week): From Day 1 (pre and post infusion) every day up to 4 weeks
Simulated Tmax of TAK-881 at Steady-State
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. Tmax was estimated for the simulated PK profiles and summarized by age group. Median and full range derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
Time frame: During the dosing interval of 6th dose (4-week): From Day 1 (pre and post infusion) every day up to 4 weeks
Simulated t1/2 of TAK-881 at Steady-State
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. t1/2 was estimated for the simulated PK profiles and summarized by age group. Geometric mean and 90% PI derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
Time frame: During the dosing interval of 6th dose (4-week): From Day 1 (pre and post infusion) every day up to 4 weeks
Simulated CL/F of TAK-881 at Steady-State
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. CL/F was estimated for the simulated PK profiles and summarized by age group. Geometric mean and 90% PI derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
Time frame: During the dosing interval of 6th dose (4-week): From Day 1 (pre and post infusion) every day up to 4 weeks
Simulated Vz/F of TAK-881 at Steady-State
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. Vz/F was estimated for the simulated PK profiles and summarized by age group. Geometric mean and 90% PI derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
Time frame: During the dosing interval of 6th dose (4-week): From Day 1 (pre and post infusion) every day up to 4 weeks
Simulated AUC0-tau;ss/Week of TAK-881 at Steady-State
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. AUC0-tau;ss/week was estimated for the simulated PK profiles and summarized by age group. Geometric mean and 90% PI derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
Time frame: During the dosing interval of 6th dose (4-week): From Day 1 (pre and post infusion) every day up to 4 weeks
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical study subject, temporally associated with the use of the study intervention, whether or not the occurrence is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study intervention. A TEAE was defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.
Time frame: From the start of study drug administration, up to 27 weeks (Single arm treatment) and up to 51 weeks (Crossover treatment)
Number of Participants With Infusion Withdrawals, Interruptions, or Infusion Rate Reductions Due to TAK-881-related TEAEs
Number of participants with infusion withdrawals, interruptions, or infusion rate reductions due to TAK-881-related TEAEs were reported.
Time frame: From the start of study drug administration, up to 23 weeks (Single arm treatment) and up to 48 weeks (Crossover treatment)
Number of Participants With Positive Binding Antibodies (Titer Greater Than and Equal to [>=] 1:160) and Positive Neutralizing Antibodies to Recombinant Human Hyaluronidase PH20 (rHuPH20)
Participants were considered "Positive" if corresponding titer is \>=1:160 and were considered "Negative" if no anti-drug antibodies (ADA) is quantified (negative assay result) or the corresponding titer is \<1:160.
Time frame: From the start of study drug administration, up to 23 weeks (Single arm treatment) and up to 51 weeks (Crossover treatment)
Number of Infusions Per Month at Full Dose With Both TAK-881 and HYQVIA
Number of infusion per month at full dose was calculated as the total number of full dose infusions divided by the total time in months on treatment. A single aggregate value was therefore presented; a measure of dispersion was not applicable.
Time frame: Single arm treatment: Up to 20 weeks; Crossover treatment: Up to 45 weeks
Duration of Infusions Per Participant at Full Dose With Both TAK-881 and HYQVIA
The sum of the following: 1) Stop time of rHuPH20 - start time of rHuPH20; 2) Sum of all individual IgG duration steps; 3) Start time of IgG - Stop time of rHuPH20, 4) Duration of all IgG interruptions independent of the reason for interruption. For each participant, the average infusion duration was calculated; participant-level averages were then summarized using median and full range.
Time frame: Single arm treatment: Up to 20 weeks; Crossover treatment: Up to 45 weeks
Monthly Infusion Time Per Participant at Full Dose With Both TAK-881 and HYQVIA
Monthly infusion time per participant at full dose was calculated as the total duration of full dose infusions per treatment divided by the total time in months on the respective treatment. For each participant, the average monthly infusion time was calculated; participant-level averages were then summarized using median and full range.
Time frame: Single arm treatment: Up to 20 weeks; Crossover treatment: Up to 45 weeks
Number of Infusion Sites (Needle Sticks) Per Infusion at Full Dose With Both TAK-881 and HYQVIA
Number of infusion sites per infusion at full dose was calculated as the total number of full dose infusion sites divided by the total number of full dose infusions with an available infusion site. A single aggregate value was therefore presented; a measure of dispersion was not applicable.
Time frame: Single arm treatment: Up to 20 weeks; Crossover treatment: Up to 45 weeks
Number of Infusion Sites (Needle Sticks) Per Month at Full Dose With Both TAK-881 and HYQVIA in All Participant
Number of infusion sites per month at full dose was calculated as the total number of full dose infusion sites divided by the total time in months on treatment. A single aggregate value was therefore presented; a measure of dispersion was not applicable.
Time frame: Single arm treatment: Up to 20 weeks; Crossover treatment: Up to 45 weeks
Maximum Tolerated Infusion Rate Per Site at Full Dose With Both TAK-881 and HYQVIA
The maximum tolerated infusion rate at full dose was reported for rHuPH20 and IgG.
Time frame: Single arm treatment: Up to 20 weeks; Crossover treatment: Up to 45 weeks
Infusion Volume Per Site Per Participant at Full Dose With Both TAK-881 and HYQVIA
Infusion volume per site at full dose was reported for rHuPH20 and IgG. Infusion volume was measured in milliliters (mL), and infusion volume per site was reported in terms of mL per site per participant. For each participant, the average infusion volume per site was calculated; participant-level averages were then summarized using median and full range.
Time frame: Single arm treatment: Up to 20 weeks; Crossover treatment: Up to 45 weeks
Participants with primary immunodeficiency diseases (PIDD) took part in the study across 26 investigative sites in Czech Republic, Denmark, Spain, Greece, Netherlands, Poland, Slovakia, and United States from 24 October 2023 to 20 January 2026. Participants previously treated with IGIV or HYQVIA maintained their prestudy 3- or 4-week dosing interval. For participants previously treated with conventional IGSC, the 3- or 4-week dosing interval was selected by the investigator at screening.
| Milestone | Single Arm Treatment: TAK-881 (2 to <16 Years) | Sequence 1 (AB): TAK-881 Followed by HYQVIA (>=16 Years) | Sequence 2 (BA): HYQVIA Followed by TAK-881 (>=16 Years) |
|---|---|---|---|
| Started | 22 | 22 | 21 |
| Completed | 22 | 17 | 19 |
| Not completed | 0 | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 |
| Withdrew: Protocol violation | 0 | 3 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Milestone | Single Arm Treatment: TAK-881 (2 to <16 Years) | Sequence 1 (AB): TAK-881 Followed by HYQVIA (>=16 Years) | Sequence 2 (BA): HYQVIA Followed by TAK-881 (>=16 Years) |
|---|---|---|---|
| Started | 0 | 17 | 19 |
| Completed | 0 | 15 | 19 |
| Not completed | 0 | 2 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
AUC0-tau;ss was defined as the area under the curve over one dosing interval at steady-state. The AUC0-tau;ss was calculated during the dosing interval after the last dose in each crossover epoch by the non-compartmental analysis (NCA) based on total IgG levels for TAK-881 and HYQVIA.
| days*gram per liter (day*g/L) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|
| Area Under the Curve Over One Dosing Interval at Steady-State (AUC0-tau;ss) of Total IgG Levels With TAK-881 and HYQVIA Treatment in Participants >= 16 Years | 326 (296 to 359) | 327 (297 to 360) |
Mean annualized rates and corresponding two-sided 95% CIs were reported for TAK-881 and HYQVIA and were analyzed using a generalized linear model. The response distribution was assumed to be Poisson with a logarithmic link function. The model included the natural logarithm of the length of the observational period in years as an offset to account for potential differences in lengths of the observational periods per participant. Results were back transformed from the logarithmic scale.
| infections per participant year | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Mean Annualized Rate of All Infections | 5.37 (3.78 to 7.36) | 2.62 (1.75 to 3.76) | 2.73 (1.85 to 3.86) |
Mean annualized rates of ASBIs and corresponding two-sided 95% CIs were reported for TAK-881 and HYQVIA and were analyzed using a generalized linear model. The response distribution was assumed to be Poisson with a logarithmic link function. The model included the natural logarithm of the length of the observational period in years as an offset to account for potential differences in lengths of the observational periods per participant. Results were back transformed from the logarithmic scale.
| ASBI per participant year | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Mean Annualized Rate of Acute Serious Bacterial Infections (ASBIs) | 0.0926 (0.0259 to 0.227) | 0.0558 (0.0197 to 0.121) | 0 (0 to 0.214) |
Mean annualized rates of fever episodes and corresponding two-sided 95% CIs were reported for TAK-881 and HYQVIA and were analyzed using a generalized linear model. The response distribution was assumed to be Poisson with a logarithmic link function. The model included the natural logarithm of the length of the observational period in years as an offset to account for potential differences in lengths of the observational periods per participant. Results were back transformed from the logarithmic scale.
| fever episodes per participant year | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Mean Annualized Rate of Fever Episodes | 1.76 (1.01 to 2.81) | 0.558 (0.287 to 0.964) | 0.232 (0.103 to 0.441) |
The time to first ASBI was defined as the time between the first investigational product (IP) administration (referring to the first ramp-up dose, if ramp-up is applicable, or to the first full dose at Week 1, if ramp-up is not applicable) and the first occurrence of the ASBI. The median time to first ASBI was reported.
| days | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Time to First ASBI | 173.0 (173 to 173) | 56.0 (56 to 56) | — |
The median duration of infections was reported. Only participants with an infection are included here.
| days | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Duration of Infections | 9.0 (2 to 49) | 9.0 (1 to 56) | 9.0 (1 to 196) |
The mean number of days with daily activity impairment per participant-year was reported.
| days per participant year | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Number of Days Not Able to go to School, Work, Daycare, or to Perform Normal Daily Activities Due to Infections and/or Their Treatment, or Other Illnesses | 13.1 ± 25.54 | 17.6 ± 58.57 | 13.8 ± 34.49 |
Days on antibiotics were calculated as the total number of calendar days during which at least one respective antibiotic was administered due to treatment of infection. Data was collected for administration via oral or parenteral and all routes. The mean number of days on antibiotics per participant-year was reported.
| days per participant year | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Oral/ Parenteral Route | 13.8 ± 20.40 | 19.7 ± 37.91 | 16.3 ± 25.86 |
| All Routes | 18.4 ± 25.65 | 19.7 ± 37.91 | 16.7 ± 26.83 |
Number of participants hospitalized due to infection or other illnesses were reported.
| Participants | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Number of Participants Hospitalized Due to Infection or Other Illnesses | 3 | 1 | 1 |
The number of days of hospitalization due to infection per participant-year was reported.
| days per participant year | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Number of Days of Hospitalization Due to Infections or Other Illnesses | 2.0 ± 6.64 | 1.8 ± 11.30 | 0.2 ± 1.05 |
Number of participants with acute physician visits due to infection or other illnesses was reported.
| Participants | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Number of Participants With Acute Physician Visits Due to Infection or Other Illnesses | 16 | 18 | 16 |
Cmax of total IgG with TAK-881 and HYQVIA at steady-state was reported.
| gram per litre (g/L) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|
| Maximum Concentration (Cmax) of Total IgG With TAK-881 and HYQVIA at Steady-State in Participants >=16 Years | 15.9 (14.4 to 17.5) | 16.1 (14.6 to 17.8) |
Tmax of total IgG with TAK-881 and HYQVIA at steady-state was reported.
| days | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|
| Time to Maximum Concentration (Tmax) of Total IgG With TAK-881 and HYQVIA at Steady-State in Participants >=16 Years | 6.81 (0.91 to 13.90) | 3.07 (1.13 to 21.93) |
t1/2 of total IgG with TAK-881 and HYQVIA at steady-state was reported. t1/2 was estimated by noncompartmental analysis from the terminal elimination-rate constant derived from the slope of the log-linear decline in total IgG concentrations during the terminal phase of the concentration-time profile. The estimated t1/2 may exceed the 21- or 28-day PK sampling interval. The PK assessment period did not extend beyond the protocol-defined 21-day or 28-day interval.
| days | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|
| Terminal Half-life (t1/2) of Total IgG With TAK-881 and HYQVIA at Steady-State in Participants >=16 Years | 70.8 (43.3 to 116) | 58.5 (35.8 to 95.6) |
CL/F of total IgG with TAK-881 and HYQVIA at steady-state was reported.
| milliliters per day (mL/day) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|
| Apparent Clearance (CL/F) of Total IgG With TAK-881 and HYQVIA at Steady-State in Participants >=16 Years | 123 (106 to 144) | 125 (108 to 146) |
Vz/F of total IgG with TAK-881 and HYQVIA at steady-state was reported.
| milliliters (mL) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Total IgG With TAK-881 and HYQVIA at Steady-State in Participants >=16 Years | 9340 (6000 to 14500) | 8070 (5180 to 12600) |
AUC0-tau;ss/week of total IgG with TAK-881 and HYQVIA at steady-state was reported.
| day*g/L/week | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|
| AUC0-tau;ss Per Week (AUC0-tau;ss/Week) of Total IgG With TAK-881 and HYQVIA at Steady-State in Participants >=16 Years | 94.1 (85.4 to 104) | 94.4 (85.7 to 104) |
The trough level of total IgG was reported. Total IgG trough levels were analyzed using the last trough level per participants (at the end of the last dosing interval).
| g/L | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Trough Level of Total IgG | 9.25 (7.86 to 10.9) | 11.7 (10.4 to 13.1) | 11.9 (10.6 to 13.4) |
The trough level of IgG subclasses was reported. Trough levels of IgG subclasses were analyzed using the last trough level per participants (at the end of the last dosing interval).
| g/L | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| IgG1 | 5.07 (4.35 to 5.91) | 6.59 (5.91 to 7.34) | 6.62 (5.94 to 7.38) |
| IgG2 | 2.95 (2.65 to 3.29) | 3.71 (3.30 to 4.17) | 3.72 (3.31 to 4.17) |
| IgG3 | 0.198 (0.165 to 0.238) | 0.270 (0.230 to 0.317) | 0.274 (0.233 to 0.321) |
| IgG4 | 0.271 (0.197 to 0.372) | 0.373 (0.277 to 0.504) | 0.396 (0.294 to 0.535) |
The trough level of antigen specific IgG antibodies (Clostridium tetani toxoid, Haemophilus influenzae, and hepatitis B) was reported. Antigen-specific IgG antibodies were analyzed using the last trough level per participant in each crossover epoch (at the end of the last dosing interval).
| international units/ milliliter (IU/mL) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|
| Antibodies to Clostridium Tetani Toxoid | 1.84 (1.51 to 2.24) | 1.65 (1.35 to 2.01) |
| Antibodies to Haemophilus Influenzae | 1.60 (1.23 to 2.07) | 1.73 (1.33 to 2.24) |
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. AUC0-tau;ss was estimated for the simulated PK profiles and summarized by age group. Geometric mean and 90% predicted interval (PI) derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
| g*day/L | Population PK: TAK-881 (2 to <16 Years) | Population PK: TAK-881 (>=16 Years) |
|---|---|---|
| Simulated AUC0-tau;ss of TAK-881 at Steady-State | 270 (210 to 386) | 306 (227 to 460) |
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. Cmax was estimated for the simulated PK profiles and summarized by age group. Geometric mean and 90% PI derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
| g/L | Population PK: TAK-881 (2 to <16 Years) | Population PK: TAK-881 (>=16 Years) |
|---|---|---|
| Simulated Cmax of TAK-881 at Steady-State | 11.2 (8.83 to 15.4) | 12.5 (9.48 to 18.1) |
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. Tmax was estimated for the simulated PK profiles and summarized by age group. Median and full range derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
| days | Population PK: TAK-881 (2 to <16 Years) | Population PK: TAK-881 (>=16 Years) |
|---|---|---|
| Simulated Tmax of TAK-881 at Steady-State | 4.00 (2.00 to 5.00) | 4.00 (2.00 to 5.00) |
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. t1/2 was estimated for the simulated PK profiles and summarized by age group. Geometric mean and 90% PI derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
| days | Population PK: TAK-881 (2 to <16 Years) | Population PK: TAK-881 (>=16 Years) |
|---|---|---|
| Simulated t1/2 of TAK-881 at Steady-State | 81.3 (50.2 to 143) | 73.4 (47.3 to 127) |
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. CL/F was estimated for the simulated PK profiles and summarized by age group. Geometric mean and 90% PI derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
| milliliter/ day/ kilogram (mL/day/kg) | Population PK: TAK-881 (2 to <16 Years) | Population PK: TAK-881 (>=16 Years) |
|---|---|---|
| Simulated CL/F of TAK-881 at Steady-State | 1.84 (1.29 to 2.37) | 1.62 (1.08 to 2.18) |
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. Vz/F was estimated for the simulated PK profiles and summarized by age group. Geometric mean and 90% PI derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
| L/kg | Population PK: TAK-881 (2 to <16 Years) | Population PK: TAK-881 (>=16 Years) |
|---|---|---|
| Simulated Vz/F of TAK-881 at Steady-State | 0.0466 (0.0311 to 0.0667) | 0.0402 (0.0261 to 0.0581) |
Sparse PK sampling was conducted for participants aged 2 to \<16 years. A population PK model integrating PK data from participants aged 2 to \<16 years and participants aged \>=16 years was developed. Population PK simulations were performed using virtual pediatric and adult populations constructed from age- and sex-specific body weight distributions, ensuring that the simulations were representative of the target PIDD population. AUC0-tau;ss/week was estimated for the simulated PK profiles and summarized by age group. Geometric mean and 90% PI derived from the simulation (N = 3000 per age group) at the observed median of average body weight adjusted TAK-881 full-dose per participant for every-4-week dosing frequency were reported.
| day*g/L/week | Population PK: TAK-881 (2 to <16 Years) | Population PK: TAK-881 (>=16 Years) |
|---|---|---|
| Simulated AUC0-tau;ss/Week of TAK-881 at Steady-State | 67.5 (52.4 to 96.5) | 76.4 (56.8 to 115) |
An adverse event (AE) was any untoward medical occurrence in a clinical study subject, temporally associated with the use of the study intervention, whether or not the occurrence is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study intervention. A TEAE was defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.
| Participants | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 22 | 33 | 35 |
Number of participants with infusion withdrawals, interruptions, or infusion rate reductions due to TAK-881-related TEAEs were reported.
| Participants | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Infusion Rate Reduction | 7 | 1 | 1 |
| Infusion Interruption | 6 | 3 | 1 |
| Infusion Withdrawal | 0 | 0 | 0 |
Participants were considered "Positive" if corresponding titer is \>=1:160 and were considered "Negative" if no anti-drug antibodies (ADA) is quantified (negative assay result) or the corresponding titer is \<1:160.
| Participants | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881/HYQVIA and HYQVIA/TAK-881 (>=16 Years) |
|---|---|---|
| Positive Binding Antibodies | 0 | 4 |
| Positive Neutralizing Antibodies | 0 | 0 |
Number of infusion per month at full dose was calculated as the total number of full dose infusions divided by the total time in months on treatment. A single aggregate value was therefore presented; a measure of dispersion was not applicable.
| infusion per month | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Number of Infusions Per Month at Full Dose With Both TAK-881 and HYQVIA | 1.08 | 1.21 | 1.21 |
The sum of the following: 1) Stop time of rHuPH20 - start time of rHuPH20; 2) Sum of all individual IgG duration steps; 3) Start time of IgG - Stop time of rHuPH20, 4) Duration of all IgG interruptions independent of the reason for interruption. For each participant, the average infusion duration was calculated; participant-level averages were then summarized using median and full range.
| minutes per participant | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Duration of Infusions Per Participant at Full Dose With Both TAK-881 and HYQVIA | 66.8 (34.3 to 135) | 66.9 (30.7 to 121) | 95.1 (63.7 to 234) |
Monthly infusion time per participant at full dose was calculated as the total duration of full dose infusions per treatment divided by the total time in months on the respective treatment. For each participant, the average monthly infusion time was calculated; participant-level averages were then summarized using median and full range.
| minutes per month per participant | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Monthly Infusion Time Per Participant at Full Dose With Both TAK-881 and HYQVIA | 72.4 (36.2 to 150) | 80.1 (32.9 to 492) | 115 (69.6 to 570) |
Number of infusion sites per infusion at full dose was calculated as the total number of full dose infusion sites divided by the total number of full dose infusions with an available infusion site. A single aggregate value was therefore presented; a measure of dispersion was not applicable.
| number of sites per infusion | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Number of Infusion Sites (Needle Sticks) Per Infusion at Full Dose With Both TAK-881 and HYQVIA | 1.23 | 1.47 | 1.64 |
Number of infusion sites per month at full dose was calculated as the total number of full dose infusion sites divided by the total time in months on treatment. A single aggregate value was therefore presented; a measure of dispersion was not applicable.
| number of sites per month | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| Number of Infusion Sites (Needle Sticks) Per Month at Full Dose With Both TAK-881 and HYQVIA in All Participant | 1.33 | 1.77 | 1.98 |
The maximum tolerated infusion rate at full dose was reported for rHuPH20 and IgG.
| milliliter/ hour/ site (mL/hour/site) | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| rHuPH20 | 120.0 (30 to 120) | 120.0 (30 to 300) | 120.0 (60 to 120) |
| IgG | 120.0 (40 to 300) | 300.0 (120 to 300) | 300.0 (5 to 300) |
Infusion volume per site at full dose was reported for rHuPH20 and IgG. Infusion volume was measured in milliliters (mL), and infusion volume per site was reported in terms of mL per site per participant. For each participant, the average infusion volume per site was calculated; participant-level averages were then summarized using median and full range.
| mL per site per participant | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>= 16 Years) |
|---|---|---|---|
| rHuPH20 | 6.25 (2.00 to 13.0) | 13.9 (7.50 to 30.3) | 12.5 (7.50 to 28.0) |
| IgG | 62.8 (19.3 to 125) | 138 (75.0 to 298) | 250 (88.1 to 550) |
Collected over From the start of study drug administration, up to 27 weeks (Single arm treatment) and up to 51 weeks (Crossover treatment). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single Arm Treatment: TAK-881 (2 to <16 Years) | 0/22 (0%) | 3/22 (13.6%) | 21/22 (95.5%) |
| Crossover Treatment: TAK-881 (>=16 Years) | 0/41 (0%) | 1/41 (2.4%) | 31/41 (75.6%) |
| Crossover Treatment: HYQVIA (>=16 Years) | 0/38 (0%) | 3/38 (7.9%) | 31/38 (81.6%) |
| Event | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>=16 Years) |
|---|---|---|---|
| Gastritis viralInfections and infestations | 1/22 | 0/41 | 0/38 |
| InfluenzaInfections and infestations | 1/22 | 0/41 | 0/38 |
| Pneumonia aspirationInfections and infestations | 1/22 | 0/41 | 0/38 |
| AtaxiaNervous system disorders | 0/22 | 0/41 | 1/38 |
| Chest discomfortGeneral disorders | 0/22 | 0/41 | 1/38 |
| HeadacheNervous system disorders | 0/22 | 0/41 | 1/38 |
| Postoperative wound infectionInfections and infestations | 0/22 | 0/41 | 1/38 |
| SyncopeNervous system disorders | 0/22 | 0/41 | 1/38 |
| Vision blurredEye disorders | 0/22 | 0/41 | 1/38 |
| COVID-19Infections and infestations | 0/22 | 1/41 | 0/38 |
| Event | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881 (>=16 Years) | Crossover Treatment: HYQVIA (>=16 Years) |
|---|---|---|---|
| Infusion site erythemaGeneral disorders | 13/22 | 13/41 | 10/38 |
| HeadacheNervous system disorders | 10/22 | 11/41 | 8/38 |
| Infusion site painGeneral disorders | 9/22 | 8/41 | 6/38 |
| Upper respiratory tract infectionInfections and infestations | 6/22 | 7/41 | 4/38 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/22 | 0/41 | 3/38 |
| Infusion site extravasationGeneral disorders | 5/22 | 3/41 | 1/38 |
| Infusion site pruritusGeneral disorders | 5/22 | 3/41 | 5/38 |
| SinusitisInfections and infestations | 5/22 | 2/41 | 2/38 |
| FatigueGeneral disorders | 2/22 | 6/41 | 8/38 |
| COVID-19Infections and infestations | 2/22 | 2/41 | 7/38 |
The safety analysis set (SAS) included all participants who received any amount of TAK-881 or HYQVIA. As pre-specified in the statistical analysis plan (SAP), baseline characteristics data were summarized by age group.
| Age, Continuous(years) | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881/HYQVIA and HYQVIA/TAK-881 (>=16 Years) | Total |
|---|---|---|---|
| Mean | 8.2 ± 4.24 | 52.2 ± 18.23 | 37.3 ± 25.76 |
| Sex: Female, Male(Participants) | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881/HYQVIA and HYQVIA/TAK-881 (>=16 Years) | Total |
|---|---|---|---|
| Female | 9 | 24 | 33 |
| Male | 13 | 19 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881/HYQVIA and HYQVIA/TAK-881 (>=16 Years) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 21 | 42 | 63 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Single Arm Treatment: TAK-881 (2 to <16 Years) | Crossover Treatment: TAK-881/HYQVIA and HYQVIA/TAK-881 (>=16 Years) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 22 | 41 | 63 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2023 to primary completion in Jan 2026, 26 months.
Results were first posted in Sep 2026, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Primary Immunodeficiency Diseases →